Endpoint selection and relative (versus absolute) risk reporting in published medication trials.

ABSTRACT:

Background

The use of surrogate and composite endpoints, disease-specific mortality as an endpoint, and relative (rather than absolute) risk reporting in clinical trials may produce results that are misleading or difficult to interpret.

Objective

To describe the prevalence of these endpoints and of relative risk reporting in medication trials. DESIGN AND MAIN MEASURES: We analyzed all randomized medication trials published in the six highest impact general medicine journals between June 1, 2008 and September 30, 2010 and determined the percentage using these endpoints and the percentage reporting results in the abstract exclusively in relative terms.

Key results

We identified 316 medication trials, of which 116 (37%) used a surrogate primary endpoint and 106 (34%) use

SUBMITTER: Hochman M 

PROVIDER: S-EPMC3208473 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature